array:24 [
  "pii" => "S1578219017303062"
  "issn" => "15782190"
  "doi" => "10.1016/j.adengl.2017.10.003"
  "estado" => "S300"
  "fechaPublicacion" => "2017-12-01"
  "aid" => "1748"
  "copyright" => "Elsevier España, S.L.U. and AEDV"
  "copyrightAnyo" => "2017"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "fla"
  "cita" => "Actas Dermosifiliogr. 2017;108:911-7"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 522
    "formatos" => array:3 [
      "EPUB" => 18
      "HTML" => 363
      "PDF" => 141
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S0001731017303769"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2017.07.002"
      "estado" => "S300"
      "fechaPublicacion" => "2017-12-01"
      "aid" => "1748"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "fla"
      "cita" => "Actas Dermosifiliogr. 2017;108:911-7"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 463
        "formatos" => array:3 [
          "EPUB" => 1
          "HTML" => 290
          "PDF" => 172
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Original</span>"
        "titulo" => "Psoriasis moderada&#46; Propuesta de definici&#243;n"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "911"
            "paginaFinal" => "917"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Moderate Psoriasis&#58; A Proposed Definition"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "M&#46; Llamas-Velasco, P&#46; de la Cueva, J&#46; Notario, L&#46; Mart&#237;nez-Pilar, A&#46; Martorell, D&#46; Moreno-Ram&#237;rez"
            "autores" => array:6 [
              0 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Llamas-Velasco"
              ]
              1 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "de la Cueva"
              ]
              2 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Notario"
              ]
              3 => array:2 [
                "nombre" => "L&#46;"
                "apellidos" => "Mart&#237;nez-Pilar"
              ]
              4 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Martorell"
              ]
              5 => array:2 [
                "nombre" => "D&#46;"
                "apellidos" => "Moreno-Ram&#237;rez"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S1578219017303062"
          "doi" => "10.1016/j.adengl.2017.10.003"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017303062?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017303769?idApp=UINPBA000044"
      "url" => "/00017310/0000010800000010/v1_201711300829/S0001731017303769/v1_201711300829/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S1578219017303773"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2017.07.014"
    "estado" => "S300"
    "fechaPublicacion" => "2017-12-01"
    "aid" => "1743"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2017;108:918-23"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 316
      "formatos" => array:3 [
        "EPUB" => 15
        "HTML" => 252
        "PDF" => 49
      ]
    ]
    "en" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "Impact on Quality of Life in Dermatology Patients Attending an Emergency Department"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:3 [
        0 => "en"
        1 => "en"
        2 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "918"
          "paginaFinal" => "923"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Calidad de vida en pacientes dermatol&#243;gicos valorados en urgencias"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0010"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 506
              "Ancho" => 1333
              "Tamanyo" => 62683
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A&#46; Alegre-S&#225;nchez, D&#46; de Perosanz-Lobo, A&#46; Pascual-S&#225;nchez, C&#46; Pindado-Ortega, P&#46; Fonda-Pascual, &#211;&#46;M&#46; Moreno-Arrones, P&#46; Ja&#233;n-Olasolo"
          "autores" => array:7 [
            0 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Alegre-S&#225;nchez"
            ]
            1 => array:2 [
              "nombre" => "D&#46;"
              "apellidos" => "de Perosanz-Lobo"
            ]
            2 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Pascual-S&#225;nchez"
            ]
            3 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Pindado-Ortega"
            ]
            4 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Fonda-Pascual"
            ]
            5 => array:2 [
              "nombre" => "&#211;&#46;M&#46;"
              "apellidos" => "Moreno-Arrones"
            ]
            6 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Ja&#233;n-Olasolo"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0010"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S000173101730371X"
        "doi" => "10.1016/j.ad.2017.07.001"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101730371X?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017303773?idApp=UINPBA000044"
    "url" => "/15782190/0000010800000010/v1_201711300824/S1578219017303773/v1_201711300824/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S1578219017303761"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2017.04.011"
    "estado" => "S300"
    "fechaPublicacion" => "2017-12-01"
    "aid" => "1742"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "ssu"
    "cita" => "Actas Dermosifiliogr. 2017;108:902-10"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 284
      "formatos" => array:3 [
        "EPUB" => 16
        "HTML" => 176
        "PDF" => 92
      ]
    ]
    "en" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
      "titulo" => "Paraneoplastic Pemphigus&#46; A Life-Threatening Autoimmune Blistering Disease"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:3 [
        0 => "en"
        1 => "en"
        2 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "902"
          "paginaFinal" => "910"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "P&#233;nfigo paraneopl&#225;sico&#46; Una enfermedad ampollosa autoinmune grave"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0025"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 906
              "Ancho" => 1333
              "Tamanyo" => 82683
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A&#46; Tirado-S&#225;nchez, A&#46; Bonifaz"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Tirado-S&#225;nchez"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Bonifaz"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0025"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0001731017303708"
        "doi" => "10.1016/j.ad.2017.04.024"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017303708?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017303761?idApp=UINPBA000044"
    "url" => "/15782190/0000010800000010/v1_201711300824/S1578219017303761/v1_201711300824/en/main.assets"
  ]
  "en" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
    "titulo" => "Moderate Psoriasis&#58; A Proposed Definition"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "911"
        "paginaFinal" => "917"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "M&#46; Llamas-Velasco, P&#46; de la Cueva, J&#46; Notario, L&#46; Mart&#237;nez-Pilar, A&#46; Martorell, D&#46; Moreno-Ram&#237;rez"
        "autores" => array:6 [
          0 => array:4 [
            "nombre" => "M&#46;"
            "apellidos" => "Llamas-Velasco"
            "email" => array:1 [
              0 => "mar&#46;llamasvelasco&#64;gmail&#46;com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "P&#46;"
            "apellidos" => "de la Cueva"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "J&#46;"
            "apellidos" => "Notario"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "L&#46;"
            "apellidos" => "Mart&#237;nez-Pilar"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "Martorell"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "D&#46;"
            "apellidos" => "Moreno-Ram&#237;rez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:6 [
          0 => array:3 [
            "entidad" => "Departamento Dermatolog&#237;a&#44; Hospital Universitario la Princesa&#44; Instituto de Investigaci&#243;n Sanitaria la Princesa &#40;IIS-IP&#41;&#44; Madrid&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Departamento Dermatolog&#237;a&#44; Hospital Universitario Infanta Leonor&#44; Madrid&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Departamento Dermatolog&#237;a&#44; Hospital de Bellvitge&#44; Barcelona&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Departamento Dermatolog&#237;a&#44; Hospital Regional Universitario Carlos Haya&#44; M&#225;laga&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Departamento Dermatolog&#237;a&#44; Hospital de Manises&#44; Valencia&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Departamento Dermatolog&#237;a&#44; Hospital Universitario Virgen de la Macarena&#44; Sevilla&#44; Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Psoriasis moderada&#46; Propuesta de definici&#243;n"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Therapeutic decision making in patients with psoriasis is based on assessment of the severity of the disease&#44; its impact on the patients&#8217; quality of life&#44; and the presence of comorbid conditions &#40;mainly psoriatic arthritis&#44; metabolic disorders&#44; and cardiovascular risk&#41;&#46; Currently&#44; the psoriasis area severity index &#40;PASI&#41;&#44; body surface area &#40;BSA&#41;&#44; and Dermatology Life Quality Index &#40;DLQI&#41; are still considered by clinical guidelines as the most appropriate instruments for assessing the severity of cutaneous disease and its impact on quality of life&#46; The guidelines stratify the severity of psoriasis into 2 large groups in accordance with the intensity of symptoms&#58; mild psoriasis and moderate to severe psoriasis&#46; The need or indication for systemic treatment and phototherapy is limited to those patients with moderate to severe psoriasis&#44; whereas those patients with mild psoriasis are candidates for topical treatment&#46; The correct classification of severity is&#44; therefore&#44; critical for therapeutic decision making&#46;<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">1&#8211;3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">This classification&#44; however&#44; faces 2 important limitations&#46; First&#44; there is no absolute consensus on the thresholds for PASI and DLQI to provide a clinically coherent differentiation between mild and moderate to severe psoriasis&#46;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">4</span></a> Most clinical trials of biologic agents for psoriasis define moderate to severe psoriasis as PASI or BSA greater than 10 or 10&#37;&#44; respectively&#44; and DLQI greater than 10&#46;<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">5&#44;6</span></a> However&#44; the fact that assignment of patients with more severe disease to a moderate to severe group implies the same therapeutic approach for a highly heterogenous group of patients&#44; whose PASI could range from 10 to a maximum of 72&#46;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">5</span></a> Thus&#44; the consensus document of the <span class="elsevierStyleItalic">Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a</span>&#44; published in 2009 by Puig et al&#44;<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">3</span></a> already questioned whether PASI and BSA might be inadequate means for appropriately defining severity and whether factors such as site or special clinical forms should be taken into account if associated with greater psychological or social impact for the patients&#46; The update to the consensus document&#44; published in 2016&#44; also considered a combined definition of moderate to severe psoriasis as PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#37;&#44; and DLQI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; clarifying that it is not essential to use quality of life indices to include a patient in this category&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">7</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">The availability of increasingly effective treatments for psoriasis in turn demands an improved definition of severity of cutaneous and joint involvement and its impact on the patients&#8217; quality of life&#46; A more precise definition of the severity of psoriasis&#44; especially in terms of better differentiation between moderate psoriasis and severe psoriasis would enable better matching of treatment burden to disease severity and the extracutaneous repercussions&#46; The objective of this study was to propose a definition for classification of moderate psoriasis through revision of the PASI&#44; BSA&#44; and DLQI thresholds&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Method</span><p id="par0020" class="elsevierStylePara elsevierViewall">In a preliminary phase&#44; a working group was selected comprising 6 dermatologists each with at least 9 years experience in the treatment of psoriasis from 4 different autonomous communities in Spain &#40;Madrid&#44; Valencia&#44; Andalusia&#44; and Catalonia&#41;&#46; A 3-phase process was then followed&#58; 1&#41; literature review&#59; 2&#41; elaboration of a questionnaire with relevant questions to help guide the proposal&#59; and 3&#41; face-to-face meeting with critical review of the selected scientific evidence&#44; completion of the questionnaire and discussion of its content&#44; discussion of preselected clinical cases&#44; and drafting of the proposal&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">The literature search was performed by an independent scientific consultancy following a search strategy with terms pertaining to psoriasis along with different parameters used for assessing severity and quality of life and terms pertaining to diagnosis&#44; prognosis&#44; prevalence&#44; incidence&#44; therapeutic guidelines&#44; and consensuses&#46; The search strategy was restricted to studies performed in humans&#44; excluding clinical trials&#44; published from 2005 until present in Spanish or English&#44; and also included therapeutic guidelines&#44; consensus documents&#44; and assessment reports at a regional or hospital level&#46; The searches were performed using the OVID platform in the MEDLINE&#44; Embase&#44; and Cochrane databases&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Using the evidence identified &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#44; a questionnaire was drawn up that included a battery of 9 questions to be subsequently answered by the group of participating experts &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46; In the face-to-face phase&#44; the evidence identified was presented and debated&#44; and the participants filled out the questionnaire&#44; and the extent of agreement for each question was then assessed and a proposal was then drawn up for characterization of mild&#44; moderate&#44; and severe psoriasis&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">The participants presented clinical cases from their clinics which met the following pre-established criteria&#58; 1&#41; patient with PASI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10 and BSA<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10&#37;&#44; and who would therefore be considered as having mild psoriasis according to the current guidelines&#44; but given the site or impact on quality of life&#44; could potentially be considered as having moderate psoriasis&#59; and 2&#41; patient with PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 or BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#37; and who would therefore be considered as having moderate to severe psoriasis according to the current guidelines&#44; but given the site or impact on quality of life&#44; could potentially be considered as having moderate psoriasis &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#41;&#46; The clinical cases were finally reassessed according to the proposed classification&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Results</span><p id="par0040" class="elsevierStylePara elsevierViewall">The literature review identified 14 citations that included definitions of different categories of severity of psoriasis&#46;<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">7&#8211;20</span></a><a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> summarizes the definitions of psoriasis severity categories according to the main scientific societies and the European consensus that included the opinion of psoriasis experts in 19 countries&#46;<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">7&#44;8&#44;13&#44;15&#44;16</span></a> After review and discussion of the available scientific evidence&#44; completion of the questionnaire&#44; and assessment of the clinical cases presented&#44; the working group considered the following proposals&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1&#46;</span><p id="par0045" class="elsevierStylePara elsevierViewall">PASI&#44; DLQI&#44; and BSA are&#44; in order of priority and in accordance with the available evidence&#44; the parameters to use in clinical practice for classification of mild&#44; moderate&#44; and severe psoriasis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">2&#46;</span><p id="par0050" class="elsevierStylePara elsevierViewall">Assessment of the severity of psoriasis should include joint assessment and interpretation of PASI and DLQI scores&#46; Assessment of the PASI and DLQI should have the same importance for determining the severity of psoriasis&#44; because they support the assessment made by the dermatologist and are consistent with the patients&#8217; perception&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">3&#46;</span><p id="par0055" class="elsevierStylePara elsevierViewall">The PASI range 7-15 could be considered appropriate for defining moderate psoriasis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">4&#46;</span><p id="par0060" class="elsevierStylePara elsevierViewall">The DLQI range 6-10 could be considered appropriate for defining moderate psoriasis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">5&#46;</span><p id="par0065" class="elsevierStylePara elsevierViewall">The BSA range 5&#37;-10&#37; could be considered appropriate for defining moderate psoriasis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">6&#46;</span><p id="par0070" class="elsevierStylePara elsevierViewall">The presence of nail&#44; palmoplantar&#44; genital&#44; and scalp involvement could be considered moderate psoriasis due to the impact on the functional capacity of the patient when these sites are involved&#46; However&#44; it was considered that involvement of certain difficult-to-treat sites could be appropriately assessed with the DLQI&#44; and so it would not be necessary to include these sites in the definition of moderate or severe psoriasis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">7&#46;</span><p id="par0075" class="elsevierStylePara elsevierViewall">The definition of mild&#44; moderate&#44; and severe psoriasis could be based on the combination of ranges for PASI and DLQI described &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></li></ul></p><p id="par0080" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a> summarizes the responses for the questions included in the questionnaire&#44; and <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a> summarizes the outcome of the reassessment of clinical cases presented in the meeting in accordance with the definitions of the consensus&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Discussion</span><p id="par0085" class="elsevierStylePara elsevierViewall">Review of the retrieved literature highlighted the variability in terms of thresholds for PASI&#44; BSA&#44; and DLQI used in different studies for defining moderate and moderate to severe psoriasis &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">7&#8211;20</span></a> Likewise&#44; the discussion of clinical cases presented also highlighted difficulties for reaching consensus agreements among experts&#44; particularly for the classification of moderate psoriasis in patients with high PASI or BSA&#44; whereas the consensus was absolute for those patients with lower PASI or BSA&#44; regardless of the impact on DLQI&#46; This discrepancy might indicate that clinicians continue to give more weight to objective assessments &#40;PASI&#44; BSA&#41; than subjective patient-reported assessments &#40;DLQI&#41;&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">With regards the proposed definition of mild&#44; moderate&#44; and severe psoriasis&#44; 2 points are worth highlighting&#46; First&#44; the areas of uncertainty or limitations of the psoriasis severity classification have been reduced to a single scenario with 9 possible options&#46; Second&#44; the integrated application of objective assessment by the physician &#40;PASI&#41; and the patient perception &#40;DLQI&#41; is proposed&#46; This integration is particularly useful for the definition of moderate psoriasis&#46; Thus&#44; any patients with an impact on the quality of life indicated by a DLQI greater than 15 should be considered as moderate or severe psoriasis&#44; regardless of the objective assessment of the dermatologist &#40;PASI&#41;&#59; in other words&#44; a patient with DLQI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>15 could not be classified as having mild disease under any circumstances&#44; regardless of the PASI score&#46; Likewise&#44; any patient with a PASI greater than 15 would be classified as having severe psoriasis&#44; regardless of the impact of the disease on quality of life&#44; and no patient with PASI less than 7 would be classified as having severe psoriasis&#44; regardless of the impact on quality of life &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">The more appropriate characterization of patients with psoriasis according to their severity can better address needs that so far have not been met&#46; First&#44; it would homogenize groups of patients included in clinical trials&#46; Second&#44; the benefit risk assessment &#40;efficacy versus toxicity and costs&#41; that form the basis for therapeutic decisions could be adapted more exactly to the real needs of the patient&#44; thereby avoiding possible overtreatment or undertreatment&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">Another methodological limitation of the present study to take into account is that fact that a limited number of dermatologists participated &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>6&#41;&#44; and so the conclusions reached cannot be considered as robust as a consensus document&#46; Nevertheless&#44; we believe that the proposed definition and classification of moderate and severe psoriasis agreed by this working group&#44; which included experts in the management of psoriasis&#44; may serve as a starting point for debate in a representative group of experts following an appropriate method &#40;for example the Delphi method or similar&#41;&#46; Such a consensus could be used and implemented in everyday clinical practice&#44; and would without doubt lead to improved treatment of patients with psoriasis in Spain&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Ethical Responsibilities</span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Protection of human and animal subjects</span><p id="par0105" class="elsevierStylePara elsevierViewall">The authors declare that no experiments were performed on humans or animals for this investigation&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Confidentiality of data</span><p id="par0110" class="elsevierStylePara elsevierViewall">The authors declare that they have followed their hospital&#39;s protocol on the publication of data concerning patients&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Right to privacy and informed consent</span><p id="par0115" class="elsevierStylePara elsevierViewall">The authors declare that patient data do not appear in this article&#46;</p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Funding</span><p id="par0120" class="elsevierStylePara elsevierViewall">For the present study&#44; Celgene collaborated in the organization of meetings and the literature search performed by the independent scientific consultancy&#46; Nobody associated with Celgene participated in drafting the proposals or had input in other content produced by this working group or in drafting the manuscript&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Conflicts of Interest</span><p id="par0125" class="elsevierStylePara elsevierViewall">Mar Llamas-Velasco has participated in clinical trials&#44; research projects&#44; and training and consulting activities with the following companies&#58; Abbvie&#44; Celgene&#44; Galderma&#44; Janssen&#44; Leo-Pharma&#44; Lilly&#44; Novartis&#44; and Pfizer&#46;</p><p id="par0130" class="elsevierStylePara elsevierViewall">Pablo de la Cueva has participated as consultant and&#47;or investigator and&#47;or speaker for Abbvie&#44; Almirall&#44; Biogen&#44; Boehringer&#44; Celgene&#44; Janssen&#44; Leo-Pharma&#44; Lilly&#44; MSD&#44; Novartis&#44; Pfizer&#44; and UCB&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">Jaume Notario Rosa has received honoraria for consulting and training activities from Abbvie&#44; Celgene&#44; Janssen&#44; Leo-Pharma&#44; Lilly&#44; MSD&#44; Novartis&#44; and Pfizer&#46; He has participated in clinical trials and research projects sponsored by Abbvie&#44; Janssen&#44; MSD&#44; Novartis&#44; and Pfizer&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">Leandro Mart&#237;nez-Pilar has participated in research projects&#44; and training and consulting activites with the following companies&#58; Abbvie&#44; Celgene&#44; Janssen&#44; Leo-Pharma&#44; MSD&#44; Novartis&#44; and Pfizer&#46;</p><p id="par0145" class="elsevierStylePara elsevierViewall">Antonio Martorell has participated in training and consulting activities with the following companies&#58; Abbvie&#44; Celgene&#44; Janssen&#44; Isdin&#44; MSD&#44; Novartis&#44; and Pfizer&#46;</p><p id="par0150" class="elsevierStylePara elsevierViewall">David Moreno-Ram&#237;rez has participated in research projects&#44; and training and consulting activities with the following companies&#58; Abbvie&#44; Celgene&#44; Janssen&#44; Leo-Pharma&#44; Lilly&#44; MSD&#44; Novartis&#44; and Pfizer&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres949058"
          "titulo" => "Abstract"
          "secciones" => array:5 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Introduction"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Objective"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Material and methods"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Results"
            ]
            4 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec921165"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres949059"
          "titulo" => "Resumen"
          "secciones" => array:5 [
            0 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Introducci&#243;n"
            ]
            1 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Objetivo"
            ]
            2 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Material y m&#233;todos"
            ]
            3 => array:2 [
              "identificador" => "abst0045"
              "titulo" => "Resultados"
            ]
            4 => array:2 [
              "identificador" => "abst0050"
              "titulo" => "Conclusiones"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec921166"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Method"
        ]
        6 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Results"
        ]
        7 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Discussion"
        ]
        8 => array:3 [
          "identificador" => "sec0025"
          "titulo" => "Ethical Responsibilities"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Protection of human and animal subjects"
            ]
            1 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Confidentiality of data"
            ]
            2 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Right to privacy and informed consent"
            ]
          ]
        ]
        9 => array:2 [
          "identificador" => "sec0045"
          "titulo" => "Funding"
        ]
        10 => array:2 [
          "identificador" => "sec0050"
          "titulo" => "Conflicts of Interest"
        ]
        11 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2017-02-19"
    "fechaAceptado" => "2017-07-02"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec921165"
          "palabras" => array:5 [
            0 => "Psoriasis"
            1 => "Moderate-to-severe"
            2 => "Severity"
            3 => "Criterion"
            4 => "Moderate"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec921166"
          "palabras" => array:5 [
            0 => "Psoriasis"
            1 => "Moderada-grave"
            2 => "Gravedad"
            3 => "Criterio"
            4 => "Moderada"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Introduction</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The Psoriasis Area Severity Index &#40;PASI&#41; is the most widely used scale for assessing the severity of psoriasis and for therapeutic decision making&#46; On the basis of the PASI score&#44; patients have been stratified into 2 groups&#58; mild disease and moderate-to-severe disease&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Objective</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">To draft a proposal for the definition and characterization of moderate psoriasis based on PASI and Dermatology Life Quality Index &#40;DLQI&#41; scores&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Material and methods</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">A group of 6 dermatologists with experience in the treatment of psoriasis undertook a critical review of the literature and a discussion of cases to draft a proposal&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Results</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">In order of priority&#44; PASI&#44; DLQI&#44; and body surface area &#40;BSA&#41; are the parameters to be used in daily practice to classify psoriasis as mild&#44; moderate&#44; or severe&#46; Severity should be assessed on the basis of a combined evaluation and interpretation of the PASI and DLQI&#46; And 3&#44; PASI and DLQI should carry equal weight in the determination of disease severity&#46; On this basis&#44; psoriasis severity was defined using the following criteria&#58; mild&#44; PASI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>7 and DLQI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>7&#59; moderate&#44; PASI<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>7-15 and DLQI<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>5-15 &#40;classified as severe when difficult-to-treat sites are affected or when there is a significant psychosocial impact&#41;&#59; severe&#44; PASI &#62;<span class="elsevierStyleHsp" style=""></span>15&#44; independently of the DLQI score&#46;</p></span> <span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Conclusions</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">A more precise classification of psoriasis according to disease severity will improve the risk-benefit assessment essential to therapeutic decision making in these patients&#46;</p></span>"
        "secciones" => array:5 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Introduction"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Objective"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Material and methods"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Results"
          ]
          4 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Conclusions"
          ]
        ]
      ]
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Introducci&#243;n</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">El <span class="elsevierStyleItalic">Psoriasis Area Severity Index</span> &#40;PASI&#41; es la escala de medida m&#225;s utilizada para la valoraci&#243;n de la gravedad de la psoriasis y la toma de decisi&#243;n para la indicaci&#243;n de tratamiento&#46; Atendiendo a su valor se han diferenciado 2 grupos de pacientes&#58; psoriasis leve y moderada-grave&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Objetivo</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Elaborar una propuesta para la definici&#243;n y caracterizaci&#243;n de la psoriasis moderada mediante el PASI y el DLQI&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Material y m&#233;todos</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Un grupo de 6 dermat&#243;logos con experiencia en tratar psoriasis plante&#243; la revisi&#243;n cr&#237;tica de la literatura y discusi&#243;n de casos cl&#237;nicos para elaborar una propuesta&#46;</p></span> <span id="abst0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Resultados</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">1&#41; PASI&#44; DLQI y BSA son&#44; en orden de prioridad&#44; los par&#225;metros a emplear en la pr&#225;ctica cl&#237;nica para la clasificaci&#243;n de la psoriasis leve&#44; moderada y grave&#59; 2&#41; la evaluaci&#243;n de la gravedad debe incluir la evaluaci&#243;n e interpretaci&#243;n conjunta del PASI y del DLQI&#59; y 3&#41; la evaluaci&#243;n del PASI y del DLQI deber&#237;a tener igual relevancia a la hora de determinar la gravedad de la psoriasis&#46; Conforme a esto&#44; se definieron los siguientes criterios de caracterizaci&#243;n de psoriasis&#58; a&#41; leve&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>7 y DLQI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>7&#59; b&#41; moderada&#58; PASI 7-15 y DLQI 5-15 &#40;grave en caso de localizaciones de dif&#237;cil acceso para tratamientos o que supongan impacto psicosocial importante&#41;&#59; y c&#41; grave&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>15&#44; independientemente de la puntuaci&#243;n DLQI&#46;</p></span> <span id="abst0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Conclusiones</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Una mejor caracterizaci&#243;n de los pacientes en funci&#243;n de su gravedad permitir&#225; una mejora del balance de riesgos y beneficios en el que se fundamente la toma de decisiones terap&#233;uticas&#46;</p></span>"
        "secciones" => array:5 [
          0 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Introducci&#243;n"
          ]
          1 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Objetivo"
          ]
          2 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Material y m&#233;todos"
          ]
          3 => array:2 [
            "identificador" => "abst0045"
            "titulo" => "Resultados"
          ]
          4 => array:2 [
            "identificador" => "abst0050"
            "titulo" => "Conclusiones"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Please cite this article as&#58; Llamas-Velasco M&#44; de la Cueva P&#44; Notario J&#44; Mart&#237;nez-Pilar L&#44; Martorell A&#44; Moreno-Ram&#237;rez D&#46; Psoriasis moderada&#46; Propuesta de definici&#243;n&#46; Actas Dermosifiliogr&#46; 2017&#59;108&#58;911&#8211;917&#46;</p>"
      ]
    ]
    "multimedia" => array:4 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; BSA&#44; body surface area&#59; DLQI&#44; dermatology life quality index&#59; PASI&#44; psoriasis area suface index&#59; PGA&#44; physician global assessment&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Author&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Classification of Psoriasis Severity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Daud&#233;n et al&#46;&#44; 2016<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">7</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Indications &#40;Spanish Psoriasis Group&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate to severe&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 or BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 or DLQI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 or prior need for conventional systemic therapy&#44; biologics&#44; or phototherapy&#46; Disease considered severe&#58; if involvement of exposed areas with functional or psychosocial impact&#44; associated PsA&#44; erythrodermic psoriasis&#44; generalized or localized pustular psoriasis with functional or psychosocial impact&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Committee for Human Medicinal Products &#40;CHMP&#41; of the European Medicines Agency&#44; 2004<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">8</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Indications &#40;CHMP&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Mild to moderate&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10 or BSA<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10&#44; classified as mild or moderate depending on PGA<br>Moderate&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>10 or BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; controlled with topical agents&#44; classified as moderate depending on PGA<br>Moderate to severe&#58; BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; PASI<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleHsp" style=""></span>-<span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>20&#44; poor control with topical agents&#44; classified as moderate according to PGA &#40;also considered for involvement with highly infiltrated areas&#44; such as for example palmoplantar&#44; with BSA<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10&#41;<br>Severe&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>20 or BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>20 with justification for need for systemic treatment&#44; classified as severe according to PGA &#40;this could also be considered for involvement with highly infiltrated areas with BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Smith et al&#46;&#44; 2009<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">13</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Indications &#40;British Association Dermatology&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Severe&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>10 or BSA<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>10 and DLQI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 &#40;evaluation of patients with high functional or psychosocial impact&#41;&#44; if they meet at least one of the following conditions&#58; phototherapy and systemic therapies contraindicated&#44; lack of response or intolerance of systemic therapies&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Menter et al&#46;&#44; 2011<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">15</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Indications &#40;American Association of Dermatology&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Mild&#58; BSA<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>5&#59; moderate&#58; BSA&#8805;<span class="elsevierStyleHsp" style=""></span>5-<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10&#59; severe&#58; BSA<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>10&#37;&#46; The classification of severity can vary in case of involvement of areas exposed with functional or psychosocial impact&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Mrovietz U et al&#46;&#44; 2011<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">16</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">European consensus<br>&#40;19 countries&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Mild&#58; BSA<span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>10&#44; PASI<span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>10&#44; DLQI<span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>10 &#40;can be considered moderate to severe if involvement of visible areas&#44; highly infiltrated plaques&#44; recalcitrant pruritus&#44; or substantial involvement of scalp&#44; genitals&#44; palms and soles&#44; or nails&#41;<br>Moderate to severe&#58; BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; DLQI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#46; BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; DLQI<span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>10 &#40;can be considered mild if there is no impact on QoL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1607265.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Criteria for Classification of Psoriasis &#40;Scientific Societies and European Consensus&#41;&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; BSA&#44; body surface area&#59; DLQI&#44; dermatology life quality index&#59; HRQoL&#44; health-related quality of life&#59; PASI&#44; psoriasis area severity index&#59; PGA&#44; physician global assessment&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Questions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Responses Obtained<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">1&#46; List in descending order of importance the parameters you consider should be used in dermatology practice for classifying moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">First&#58; PASI &#40;54 points&#41;&#59; second&#58; DLQI &#40;46 points&#41;&#59; third&#58; BSA &#40;44 points&#41;&#59; fourth&#58; sites inaccessible for treatments or sites with substantial psychosocial impact &#40;21 points&#41;&#59; fifth&#58; prior treatments &#40;18 points&#41;&#59; sixth&#58; PGA &#40;11 points&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">2&#46; Which of the following PASI ranges do you think would be appropriate for a patient with moderate psoriasis without having any further information available&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PASI 7-12 &#40;3&#41;&#59; PASI 5-10 &#40;2&#41;&#59; PASI 7-15 &#40;1&#41;&#59; PASI 5-15 &#40;1&#41;&#59; PASI 5-20 &#40;1&#41;&#59; PASI 10-18 &#40;1&#41;&#59; PASI 10-20 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">3&#46; Which of the following BSA ranges do you think would be appropriate for a patient with moderate psoriasis without having any further information available&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">BSA 5&#37;-10&#37; &#40;6&#41;&#59; BSA 4&#37;-9&#37; &#40;1&#41;&#59; BSA 5&#37;-15&#37; &#40;1&#41;&#59; BSA 10&#37;-20&#37; &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">4&#46; Indicate which of the following PGA categories you think would be appropriate for a patient with psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PGA 3&#44; mild to moderate &#40;6&#41;&#59; PGA 4&#44; moderate &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">5&#46; Which of the following DLQI ranges do you think would be appropriate for a patient with moderate psoriasis without having any further information available&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">DLQI&#58; 6-10&#44; moderate impact on HRQoL &#40;5&#41;&#59; DLQI&#58; 11-20&#44; high impact on HRQoL &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">6&#46; Patients with involvement of areas of difficult access for treatment &#40;nail&#44; palmoplantar&#44; genital&#44; scalp&#41; could be considered moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes &#40;4&#41;&#59; No &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">7&#46; Patients in whom psoriasis has psychosocial impact on daily living in terms of social&#44; personal&#44; or work effects should be considered moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No &#40;5&#41;&#59; Yes &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">8&#46; Which group of patients should be considered within moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No response to topical treatment &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">9&#46; Which of the following situations do you think could be considered moderate psoriasis in everyday clinical practice&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 or BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; with no negative impact on HRQoL &#40;DLQI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>5&#41; &#40;6&#41;&#59; no control with topical agents and PASI of 7-12 or BSA of 5&#37;-15&#37; &#40;5&#41;&#59; areas of difficult access for treatments or areas with a substantial psychosocial impact and PASI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>5 or BSA<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>5 &#40;3&#41;&#59; no control with topical agents and DLQI of 5&#37;-15&#37; &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1607264.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Responses only shown if used at least once&#46; For question 1&#44; a value of 9 &#40;most important&#41; to 1 &#40;least important&#41; was assigned to each response item&#44; and the values assigned to each parameter by the 6 participants were summed&#59; for the remaining questions&#44; from 2 to 9&#44; the number of experts who chose each response option is shown&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Responses to the Questions Included in the Questionnaire&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; BSA&#44; body surface area&#59; DLQI&#44; dermatology life quality index&#59; PASI&#44; psoriasis area surface index&#59; PGA&#44; physician global assessment&#59; QoL&#44; quality of life&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Case Histories&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Classification of Psoriasis Severity</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Agreed Assessment After Presentation and Discussion Within the Working Group&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Reassessment According to the Agreed Definition of the Working Group&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI&#58; 5&#46;4&#59; BSA&#58; 4&#37;&#59; PGA&#58; 3&#59; DLQI&#58; 8&#46; Severe involvement of the scalp and pubic area&#44; with small plaques on the shoulders&#46; Substantial impact on social domain&#46; Treatments&#58; topical agents&#44; systemic agents&#44; conventional agents&#44; biologics &#40;discontinued for pregnancy&#41;&#46; Classified as moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis based on DLQI score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI&#58; 2&#59; BSA&#58; 2&#37;&#59; PGA&#58; 1&#59; DLQI&#58; 12&#46; Involvement of scalp&#44; nails&#44; and face&#46; Impact on social domain&#46; Topical treatment&#46; Classified as moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis based on DLQI score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI&#58; 5&#59; BSA&#58; 5&#37;&#59; PGA&#58; 3&#59; DLQI&#58; 14&#46; Involvement of backs of hands&#44; shoulders&#44; and knees&#44; Substantial impact on work domain&#46; Treatments&#58; topical agents&#44; systemic agents&#44; conventional agents&#44; biologics&#46; Classified as mild&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis based on DLQI score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI&#58; 13&#46;8&#59; BSA&#58; 12&#37;&#59; PGA&#58; 3&#59; DLQI&#58; 4&#46; Extensive plaques on lower limbs&#44; back&#44; shoulders&#44; and backs of hands&#46; Substantial impact on work domain&#46; Intense pruritus&#46; Little impact on QoL &#40;due to advanced age&#41;&#46; Treatments&#58; topical&#44; conventional systemic agents&#46; Classified as moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis based on DLQI score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI&#58; 12&#59; BSA&#58; 13&#37;&#59; PGA&#58; 4&#59; DLQI&#58; 2&#46; Extensive involvement of forearms&#44; trunk&#44; legs&#44; back&#44; shoulders&#44; and backs of hands&#46; Substantial impact on work domain&#46; Intense pruritus&#46; Little impact on QoL&#46; Treatment&#58; topical agents Classified as moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis based on DLQI score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI&#58; 11&#59; BSA&#58; 8&#37;&#59; PGA&#58; 3&#59; DLQI&#58; 2&#46; Involvement of lower limbs&#44; little impact on QoL&#46; Treatment&#58; topical agents&#46; Classified as moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis based on DLQI score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1607266.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Classification of the Selected Case Histories&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; DLQI&#44; dermatology life quality index&#59; PASI&#44; psoriasis area severity index&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Classification of Psoriasis Severity</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI and DLQI Thresholds&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PASI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PASI 7-15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">DLQI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Mild&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Severe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">DLQI 5-15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Severe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">DLQI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Severe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1607263.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Considered severe in case of sites of difficult access for treatments or which have substantial psychosocial impact&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Proposed Classification and Definition of Mild&#44; Moderate to Severe&#44; and Severe Psoriasis According to PASI and DLQI Thresholds&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:20 [
            0 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevalencia de la psoriasis en Espa&#241;a en la era de los agentes biol&#243;gicos"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "C&#46; Ferr&#225;ndiz"
                            1 => "J&#46;M&#46; Carrascosa"
                            2 => "M&#46; Toro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2013.12.008"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2014"
                        "volumen" => "105"
                        "paginaInicial" => "504"
                        "paginaFinal" => "509"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24569109"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46;B&#46; Kimball"
                            1 => "D&#46; Gladman"
                            2 => "J&#46;M&#46; Gelfand"
                            3 => "K&#46; Gordon"
                            4 => "E&#46;J&#46; Horn"
                            5 => "N&#46;J&#46; Korman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2008.01.006"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2008"
                        "volumen" => "58"
                        "paginaInicial" => "1031"
                        "paginaFinal" => "1042"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18313171"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Documento de consenso sobre la evaluaci&#243;n y el tratamiento de la psoriasis moderada&#47;grave del Grupo Espa&#241;ol de Psoriasis de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Puig"
                            1 => "X&#46; Bordas"
                            2 => "J&#46;M&#46; Carrascosa"
                            3 => "E&#46; Daud&#233;n"
                            4 => "C&#46; Ferr&#225;ndiz"
                            5 => "J&#46;M&#46; Hernanz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2009"
                        "volumen" => "100"
                        "paginaInicial" => "277"
                        "paginaFinal" => "286"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19463230"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis causes as much disability as other major medical diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46;R&#46; Rapp"
                            1 => "S&#46;R&#46; Feldman"
                            2 => "M&#46;L&#46; Exum"
                            3 => "A&#46;B&#46; Fleischer Jr&#46;"
                            4 => "D&#46;M&#46; Reboussin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "1999"
                        "volumen" => "41"
                        "paginaInicial" => "401"
                        "paginaFinal" => "407"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10459113"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Quality of life in patients with psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "M&#46;J&#46; Bhosle"
                            1 => "A&#46; Kulkarni"
                            2 => "S&#46;R&#46; Feldman"
                            3 => "R&#46; Balkrishnan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1477-7525-4-35"
                      "Revista" => array:5 [
                        "tituloSerie" => "Health Qual Life Outcomes"
                        "fecha" => "2006"
                        "volumen" => "4"
                        "paginaInicial" => "35"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16756666"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Impacto de la psoriasis en la calidad de vida relacionada con la salud"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "C&#46; Ferr&#225;ndiz Foraster"
                            1 => "A&#46; Garc&#237;a-D&#237;ez"
                            2 => "L&#46; Liz&#225;n Tudela"
                            3 => "L&#46; Berm&#250;dez-Rey"
                            4 => "X&#46; Badia Llach"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Med Clin &#40;Barc&#41;"
                        "fecha" => "2007"
                        "volumen" => "128"
                        "paginaInicial" => "325"
                        "paginaFinal" => "329"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Consensus document on the evaluation and treatment of moderate-to-severe psoriasis&#58; Psoriasis Group of the Spanish Academy of Dermatology and Venereology"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "E&#46; Daud&#233;n"
                            1 => "L&#46; Puig"
                            2 => "C&#46; Ferr&#225;ndiz"
                            3 => "J&#46;L&#46; S&#225;nchez-Carazo"
                            4 => "J&#46;M&#46; Hernanz-Hermosa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.13542"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2016"
                        "volumen" => "30"
                        "numero" => "Suppl 2"
                        "paginaInicial" => "1"
                        "paginaFinal" => "18"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26812550"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Committee for medical producs for human use of EMEA&#46; Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis&#46; European Medicines Agency Evaluation of Medicines for Human Use&#44; EMEA&#47;CHMP&#47;EWP&#47;2454&#47;02 &#91;consultado 10 Agos 2015&#93;&#46; Disponible en&#58; <a href="http://www.ema.europa.eu/">http&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;</a>"
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EUROPSO&#46; European patient perspectives on the impact of psoriasis&#58; The EUROPSO patient membership survey&#46; Patient Survey Group"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Dubertret"
                            1 => "U&#46; Mrowietz"
                            2 => "A&#46; Ranki"
                            3 => "P&#46;C&#46; van de Kerkhof"
                            4 => "S&#46; Chimenti"
                            5 => "T&#46; Lotti"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2006.07405.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2006"
                        "volumen" => "155"
                        "paginaInicial" => "729"
                        "paginaFinal" => "736"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16965422"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "What characterizes the severity of psoriasis&#63; Results from an epidemiological study of over 3&#44;300 patients in the Iberian region"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "A&#46; Garc&#237;a-Diez"
                            1 => "C&#46;F&#46; Foraster"
                            2 => "F&#46;V&#46; Sebasti&#225;n"
                            3 => "L&#46;L&#46; Tudela"
                            4 => "X&#46;B&#46; Llach"
                            5 => "G&#46;S&#46; Fern&#225;ndez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000111511"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatology"
                        "fecha" => "2008"
                        "volumen" => "216"
                        "paginaInicial" => "137"
                        "paginaFinal" => "151"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18216476"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Quality of psoriasis care in Germany--results of the national study PsoHealth 2007"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Augustin"
                            1 => "K&#46; Reich"
                            2 => "C&#46; Reich"
                            3 => "S&#46; Purwins"
                            4 => "S&#46; Jeff Rustenbach"
                            5 => "I&#46; Sch&#228;fer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1610-0387.2008.06807.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dtsch Dermatol Ges"
                        "fecha" => "2008"
                        "volumen" => "6"
                        "paginaInicial" => "640"
                        "paginaFinal" => "645"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18801145"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study &#40;FUTURE&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "K&#46; Reich"
                            1 => "D&#46; Thaci"
                            2 => "U&#46; Mrowietz"
                            3 => "A&#46; Kamps"
                            4 => "M&#46; Neureither"
                            5 => "T&#46; Luger"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1610-0387.2009.07120.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dtsch Dermatol Ges"
                        "fecha" => "2009"
                        "volumen" => "7"
                        "paginaInicial" => "603"
                        "paginaFinal" => "611"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19459898"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "British Association of Dermatologists&#8217; guidelines for biologic interventions for psoriasis 2009"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;H&#46; Smith"
                            1 => "A&#46;V&#46; Anstey"
                            2 => "J&#46;N&#46; Barker"
                            3 => "A&#46;D&#46; Burden"
                            4 => "R&#46;J&#46; Chalmers"
                            5 => "D&#46;A&#46; Chandler"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2009.09505.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2009"
                        "volumen" => "161"
                        "paginaInicial" => "987"
                        "paginaFinal" => "1019"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19857207"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Scoring and monitoring the severity of psoriasis&#46; What is the preferred method&#63; What is the ideal method&#63; Is PASI pass&#233;&#63; Facts and controversies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "L&#46; Naldi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.clindermatol.2009.03.001"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clinics in Dermatology"
                        "fecha" => "2010"
                        "volumen" => "28"
                        "paginaInicial" => "67"
                        "paginaFinal" => "72"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20082954"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Guidelines of care for the management of psoriasis and psoriatic arthritis&#58; Section 6&#46; Guidelines of care for the treatment of psoriasis and psoriatic arthritis&#58; case-based presentations and evidence-based conclusions"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "American Academy of Dermatology Work Group"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Menter"
                            1 => "N&#46;J&#46; Korman"
                            2 => "C&#46;A&#46; Elmets"
                            3 => "S&#46;R&#46; Feldman"
                            4 => "J&#46;M&#46; Gelfand"
                            5 => "K&#46;B&#46; Gordon"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2010.11.055"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2011"
                        "volumen" => "65"
                        "paginaInicial" => "137"
                        "paginaFinal" => "174"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21306785"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Definition of treatment goals for moderate to severe psoriasis&#58; A European consensus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "U&#46; Mrowietz"
                            1 => "K&#46; Kragballe"
                            2 => "K&#46; Reich"
                            3 => "P&#46; Spuls"
                            4 => "C&#46;E&#46; Griffiths"
                            5 => "A&#46; Nast"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00403-010-1080-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Dermatol Res"
                        "fecha" => "2011"
                        "volumen" => "303"
                        "paginaInicial" => "1"
                        "paginaFinal" => "10"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20857129"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A review of health outcomes in patients with psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "K&#46; Li"
                            1 => "A&#46;W&#46; Armstrong"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.det.2011.08.012"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatol Clin"
                        "fecha" => "2012"
                        "volumen" => "30"
                        "paginaInicial" => "61"
                        "paginaFinal" => "67"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22117868"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevalence of metabolic syndrome in patients with psoriasis&#58; A population-based study in the United Kingdom"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;M&#46; Langan"
                            1 => "N&#46;M&#46; Seminara"
                            2 => "D&#46;B&#46; Shin"
                            3 => "A&#46;B&#46; Troxel"
                            4 => "S&#46;E&#46; Kimmel"
                            5 => "N&#46;N&#46; Mehta"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/jid.2011.365"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Invest Dermatol"
                        "fecha" => "2012"
                        "volumen" => "132"
                        "paginaInicial" => "556"
                        "paginaFinal" => "562"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22113483"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Flor-Garc&#237;a A&#44; Mart&#237;nez-Valdivieso L&#44; Ortiz-Navarro MR&#46; Informe t&#233;cnico de terapias biol&#243;gicas en dermatolog&#237;a&#58; artritis psori&#225;sica y psoriasis&#46; Servicio de Salud de Castilla la Mancha&#44; mayo de 2012 &#91;consultado 10 Oct 2015&#93;&#46; Disponible en&#58; <a href="http://sescam.castillalamancha.es/">http&#58;&#47;&#47;sescam&#46;castillalamancha&#46;es&#47;</a>"
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis vulgaris&#58; An evidence-based guide for primary care"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "E&#46;A&#46; Kupetsky"
                            1 => "M&#46; Keller"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3122/jabfm.2013.06.130055"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Board Fam Med"
                        "fecha" => "2013"
                        "volumen" => "26"
                        "paginaInicial" => "787"
                        "paginaFinal" => "801"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24204077"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/15782190/0000010800000010/v1_201711300824/S1578219017303062/v1_201711300824/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6155"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Original Articles"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010800000010/v1_201711300824/S1578219017303062/v1_201711300824/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017303062?idApp=UINPBA000044"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Original Article
Moderate Psoriasis: A Proposed Definition
Psoriasis moderada. Propuesta de definición
M. Llamas-Velascoa,
Autor para correspondencia
mar.llamasvelasco@gmail.com

Corresponding author.
, P. de la Cuevab, J. Notarioc, L. Martínez-Pilard, A. Martorelle, D. Moreno-Ramírezf
a Departamento Dermatología, Hospital Universitario la Princesa, Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain
b Departamento Dermatología, Hospital Universitario Infanta Leonor, Madrid, Spain
c Departamento Dermatología, Hospital de Bellvitge, Barcelona, Spain
d Departamento Dermatología, Hospital Regional Universitario Carlos Haya, Málaga, Spain
e Departamento Dermatología, Hospital de Manises, Valencia, Spain
f Departamento Dermatología, Hospital Universitario Virgen de la Macarena, Sevilla, Spain
Leído
9599
Veces
se ha leído el artículo
3287
Total PDF
6312
Total HTML
Compartir estadísticas
 array:24 [
  "pii" => "S1578219017303062"
  "issn" => "15782190"
  "doi" => "10.1016/j.adengl.2017.10.003"
  "estado" => "S300"
  "fechaPublicacion" => "2017-12-01"
  "aid" => "1748"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
  "copyrightAnyo" => "2017"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "fla"
  "cita" => "Actas Dermosifiliogr. 2017;108:911-7"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 522
    "formatos" => array:3 [
      "EPUB" => 18
      "HTML" => 363
      "PDF" => 141
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S0001731017303769"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2017.07.002"
      "estado" => "S300"
      "fechaPublicacion" => "2017-12-01"
      "aid" => "1748"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "fla"
      "cita" => "Actas Dermosifiliogr. 2017;108:911-7"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 463
        "formatos" => array:3 [
          "EPUB" => 1
          "HTML" => 290
          "PDF" => 172
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Original</span>"
        "titulo" => "Psoriasis moderada&#46; Propuesta de definici&#243;n"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "911"
            "paginaFinal" => "917"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Moderate Psoriasis&#58; A Proposed Definition"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "M&#46; Llamas-Velasco, P&#46; de la Cueva, J&#46; Notario, L&#46; Mart&#237;nez-Pilar, A&#46; Martorell, D&#46; Moreno-Ram&#237;rez"
            "autores" => array:6 [
              0 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Llamas-Velasco"
              ]
              1 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "de la Cueva"
              ]
              2 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Notario"
              ]
              3 => array:2 [
                "nombre" => "L&#46;"
                "apellidos" => "Mart&#237;nez-Pilar"
              ]
              4 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Martorell"
              ]
              5 => array:2 [
                "nombre" => "D&#46;"
                "apellidos" => "Moreno-Ram&#237;rez"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S1578219017303062"
          "doi" => "10.1016/j.adengl.2017.10.003"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017303062?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017303769?idApp=UINPBA000044"
      "url" => "/00017310/0000010800000010/v1_201711300829/S0001731017303769/v1_201711300829/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S1578219017303773"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2017.07.014"
    "estado" => "S300"
    "fechaPublicacion" => "2017-12-01"
    "aid" => "1743"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2017;108:918-23"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 316
      "formatos" => array:3 [
        "EPUB" => 15
        "HTML" => 252
        "PDF" => 49
      ]
    ]
    "en" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "Impact on Quality of Life in Dermatology Patients Attending an Emergency Department"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:3 [
        0 => "en"
        1 => "en"
        2 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "918"
          "paginaFinal" => "923"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Calidad de vida en pacientes dermatol&#243;gicos valorados en urgencias"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0010"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 506
              "Ancho" => 1333
              "Tamanyo" => 62683
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A&#46; Alegre-S&#225;nchez, D&#46; de Perosanz-Lobo, A&#46; Pascual-S&#225;nchez, C&#46; Pindado-Ortega, P&#46; Fonda-Pascual, &#211;&#46;M&#46; Moreno-Arrones, P&#46; Ja&#233;n-Olasolo"
          "autores" => array:7 [
            0 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Alegre-S&#225;nchez"
            ]
            1 => array:2 [
              "nombre" => "D&#46;"
              "apellidos" => "de Perosanz-Lobo"
            ]
            2 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Pascual-S&#225;nchez"
            ]
            3 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Pindado-Ortega"
            ]
            4 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Fonda-Pascual"
            ]
            5 => array:2 [
              "nombre" => "&#211;&#46;M&#46;"
              "apellidos" => "Moreno-Arrones"
            ]
            6 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Ja&#233;n-Olasolo"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0010"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S000173101730371X"
        "doi" => "10.1016/j.ad.2017.07.001"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101730371X?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017303773?idApp=UINPBA000044"
    "url" => "/15782190/0000010800000010/v1_201711300824/S1578219017303773/v1_201711300824/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S1578219017303761"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2017.04.011"
    "estado" => "S300"
    "fechaPublicacion" => "2017-12-01"
    "aid" => "1742"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "ssu"
    "cita" => "Actas Dermosifiliogr. 2017;108:902-10"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 284
      "formatos" => array:3 [
        "EPUB" => 16
        "HTML" => 176
        "PDF" => 92
      ]
    ]
    "en" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
      "titulo" => "Paraneoplastic Pemphigus&#46; A Life-Threatening Autoimmune Blistering Disease"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:3 [
        0 => "en"
        1 => "en"
        2 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "902"
          "paginaFinal" => "910"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "P&#233;nfigo paraneopl&#225;sico&#46; Una enfermedad ampollosa autoinmune grave"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0025"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 906
              "Ancho" => 1333
              "Tamanyo" => 82683
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A&#46; Tirado-S&#225;nchez, A&#46; Bonifaz"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Tirado-S&#225;nchez"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Bonifaz"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0025"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0001731017303708"
        "doi" => "10.1016/j.ad.2017.04.024"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017303708?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017303761?idApp=UINPBA000044"
    "url" => "/15782190/0000010800000010/v1_201711300824/S1578219017303761/v1_201711300824/en/main.assets"
  ]
  "en" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
    "titulo" => "Moderate Psoriasis&#58; A Proposed Definition"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "911"
        "paginaFinal" => "917"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "M&#46; Llamas-Velasco, P&#46; de la Cueva, J&#46; Notario, L&#46; Mart&#237;nez-Pilar, A&#46; Martorell, D&#46; Moreno-Ram&#237;rez"
        "autores" => array:6 [
          0 => array:4 [
            "nombre" => "M&#46;"
            "apellidos" => "Llamas-Velasco"
            "email" => array:1 [
              0 => "mar&#46;llamasvelasco&#64;gmail&#46;com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "P&#46;"
            "apellidos" => "de la Cueva"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "J&#46;"
            "apellidos" => "Notario"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "L&#46;"
            "apellidos" => "Mart&#237;nez-Pilar"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "Martorell"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "D&#46;"
            "apellidos" => "Moreno-Ram&#237;rez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:6 [
          0 => array:3 [
            "entidad" => "Departamento Dermatolog&#237;a&#44; Hospital Universitario la Princesa&#44; Instituto de Investigaci&#243;n Sanitaria la Princesa &#40;IIS-IP&#41;&#44; Madrid&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Departamento Dermatolog&#237;a&#44; Hospital Universitario Infanta Leonor&#44; Madrid&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Departamento Dermatolog&#237;a&#44; Hospital de Bellvitge&#44; Barcelona&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Departamento Dermatolog&#237;a&#44; Hospital Regional Universitario Carlos Haya&#44; M&#225;laga&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Departamento Dermatolog&#237;a&#44; Hospital de Manises&#44; Valencia&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Departamento Dermatolog&#237;a&#44; Hospital Universitario Virgen de la Macarena&#44; Sevilla&#44; Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Psoriasis moderada&#46; Propuesta de definici&#243;n"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Therapeutic decision making in patients with psoriasis is based on assessment of the severity of the disease&#44; its impact on the patients&#8217; quality of life&#44; and the presence of comorbid conditions &#40;mainly psoriatic arthritis&#44; metabolic disorders&#44; and cardiovascular risk&#41;&#46; Currently&#44; the psoriasis area severity index &#40;PASI&#41;&#44; body surface area &#40;BSA&#41;&#44; and Dermatology Life Quality Index &#40;DLQI&#41; are still considered by clinical guidelines as the most appropriate instruments for assessing the severity of cutaneous disease and its impact on quality of life&#46; The guidelines stratify the severity of psoriasis into 2 large groups in accordance with the intensity of symptoms&#58; mild psoriasis and moderate to severe psoriasis&#46; The need or indication for systemic treatment and phototherapy is limited to those patients with moderate to severe psoriasis&#44; whereas those patients with mild psoriasis are candidates for topical treatment&#46; The correct classification of severity is&#44; therefore&#44; critical for therapeutic decision making&#46;<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">1&#8211;3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">This classification&#44; however&#44; faces 2 important limitations&#46; First&#44; there is no absolute consensus on the thresholds for PASI and DLQI to provide a clinically coherent differentiation between mild and moderate to severe psoriasis&#46;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">4</span></a> Most clinical trials of biologic agents for psoriasis define moderate to severe psoriasis as PASI or BSA greater than 10 or 10&#37;&#44; respectively&#44; and DLQI greater than 10&#46;<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">5&#44;6</span></a> However&#44; the fact that assignment of patients with more severe disease to a moderate to severe group implies the same therapeutic approach for a highly heterogenous group of patients&#44; whose PASI could range from 10 to a maximum of 72&#46;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">5</span></a> Thus&#44; the consensus document of the <span class="elsevierStyleItalic">Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a</span>&#44; published in 2009 by Puig et al&#44;<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">3</span></a> already questioned whether PASI and BSA might be inadequate means for appropriately defining severity and whether factors such as site or special clinical forms should be taken into account if associated with greater psychological or social impact for the patients&#46; The update to the consensus document&#44; published in 2016&#44; also considered a combined definition of moderate to severe psoriasis as PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#37;&#44; and DLQI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; clarifying that it is not essential to use quality of life indices to include a patient in this category&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">7</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">The availability of increasingly effective treatments for psoriasis in turn demands an improved definition of severity of cutaneous and joint involvement and its impact on the patients&#8217; quality of life&#46; A more precise definition of the severity of psoriasis&#44; especially in terms of better differentiation between moderate psoriasis and severe psoriasis would enable better matching of treatment burden to disease severity and the extracutaneous repercussions&#46; The objective of this study was to propose a definition for classification of moderate psoriasis through revision of the PASI&#44; BSA&#44; and DLQI thresholds&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Method</span><p id="par0020" class="elsevierStylePara elsevierViewall">In a preliminary phase&#44; a working group was selected comprising 6 dermatologists each with at least 9 years experience in the treatment of psoriasis from 4 different autonomous communities in Spain &#40;Madrid&#44; Valencia&#44; Andalusia&#44; and Catalonia&#41;&#46; A 3-phase process was then followed&#58; 1&#41; literature review&#59; 2&#41; elaboration of a questionnaire with relevant questions to help guide the proposal&#59; and 3&#41; face-to-face meeting with critical review of the selected scientific evidence&#44; completion of the questionnaire and discussion of its content&#44; discussion of preselected clinical cases&#44; and drafting of the proposal&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">The literature search was performed by an independent scientific consultancy following a search strategy with terms pertaining to psoriasis along with different parameters used for assessing severity and quality of life and terms pertaining to diagnosis&#44; prognosis&#44; prevalence&#44; incidence&#44; therapeutic guidelines&#44; and consensuses&#46; The search strategy was restricted to studies performed in humans&#44; excluding clinical trials&#44; published from 2005 until present in Spanish or English&#44; and also included therapeutic guidelines&#44; consensus documents&#44; and assessment reports at a regional or hospital level&#46; The searches were performed using the OVID platform in the MEDLINE&#44; Embase&#44; and Cochrane databases&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Using the evidence identified &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#44; a questionnaire was drawn up that included a battery of 9 questions to be subsequently answered by the group of participating experts &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46; In the face-to-face phase&#44; the evidence identified was presented and debated&#44; and the participants filled out the questionnaire&#44; and the extent of agreement for each question was then assessed and a proposal was then drawn up for characterization of mild&#44; moderate&#44; and severe psoriasis&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">The participants presented clinical cases from their clinics which met the following pre-established criteria&#58; 1&#41; patient with PASI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10 and BSA<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10&#37;&#44; and who would therefore be considered as having mild psoriasis according to the current guidelines&#44; but given the site or impact on quality of life&#44; could potentially be considered as having moderate psoriasis&#59; and 2&#41; patient with PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 or BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#37; and who would therefore be considered as having moderate to severe psoriasis according to the current guidelines&#44; but given the site or impact on quality of life&#44; could potentially be considered as having moderate psoriasis &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#41;&#46; The clinical cases were finally reassessed according to the proposed classification&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Results</span><p id="par0040" class="elsevierStylePara elsevierViewall">The literature review identified 14 citations that included definitions of different categories of severity of psoriasis&#46;<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">7&#8211;20</span></a><a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> summarizes the definitions of psoriasis severity categories according to the main scientific societies and the European consensus that included the opinion of psoriasis experts in 19 countries&#46;<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">7&#44;8&#44;13&#44;15&#44;16</span></a> After review and discussion of the available scientific evidence&#44; completion of the questionnaire&#44; and assessment of the clinical cases presented&#44; the working group considered the following proposals&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1&#46;</span><p id="par0045" class="elsevierStylePara elsevierViewall">PASI&#44; DLQI&#44; and BSA are&#44; in order of priority and in accordance with the available evidence&#44; the parameters to use in clinical practice for classification of mild&#44; moderate&#44; and severe psoriasis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">2&#46;</span><p id="par0050" class="elsevierStylePara elsevierViewall">Assessment of the severity of psoriasis should include joint assessment and interpretation of PASI and DLQI scores&#46; Assessment of the PASI and DLQI should have the same importance for determining the severity of psoriasis&#44; because they support the assessment made by the dermatologist and are consistent with the patients&#8217; perception&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">3&#46;</span><p id="par0055" class="elsevierStylePara elsevierViewall">The PASI range 7-15 could be considered appropriate for defining moderate psoriasis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">4&#46;</span><p id="par0060" class="elsevierStylePara elsevierViewall">The DLQI range 6-10 could be considered appropriate for defining moderate psoriasis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">5&#46;</span><p id="par0065" class="elsevierStylePara elsevierViewall">The BSA range 5&#37;-10&#37; could be considered appropriate for defining moderate psoriasis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">6&#46;</span><p id="par0070" class="elsevierStylePara elsevierViewall">The presence of nail&#44; palmoplantar&#44; genital&#44; and scalp involvement could be considered moderate psoriasis due to the impact on the functional capacity of the patient when these sites are involved&#46; However&#44; it was considered that involvement of certain difficult-to-treat sites could be appropriately assessed with the DLQI&#44; and so it would not be necessary to include these sites in the definition of moderate or severe psoriasis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">7&#46;</span><p id="par0075" class="elsevierStylePara elsevierViewall">The definition of mild&#44; moderate&#44; and severe psoriasis could be based on the combination of ranges for PASI and DLQI described &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></li></ul></p><p id="par0080" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a> summarizes the responses for the questions included in the questionnaire&#44; and <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a> summarizes the outcome of the reassessment of clinical cases presented in the meeting in accordance with the definitions of the consensus&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Discussion</span><p id="par0085" class="elsevierStylePara elsevierViewall">Review of the retrieved literature highlighted the variability in terms of thresholds for PASI&#44; BSA&#44; and DLQI used in different studies for defining moderate and moderate to severe psoriasis &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">7&#8211;20</span></a> Likewise&#44; the discussion of clinical cases presented also highlighted difficulties for reaching consensus agreements among experts&#44; particularly for the classification of moderate psoriasis in patients with high PASI or BSA&#44; whereas the consensus was absolute for those patients with lower PASI or BSA&#44; regardless of the impact on DLQI&#46; This discrepancy might indicate that clinicians continue to give more weight to objective assessments &#40;PASI&#44; BSA&#41; than subjective patient-reported assessments &#40;DLQI&#41;&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">With regards the proposed definition of mild&#44; moderate&#44; and severe psoriasis&#44; 2 points are worth highlighting&#46; First&#44; the areas of uncertainty or limitations of the psoriasis severity classification have been reduced to a single scenario with 9 possible options&#46; Second&#44; the integrated application of objective assessment by the physician &#40;PASI&#41; and the patient perception &#40;DLQI&#41; is proposed&#46; This integration is particularly useful for the definition of moderate psoriasis&#46; Thus&#44; any patients with an impact on the quality of life indicated by a DLQI greater than 15 should be considered as moderate or severe psoriasis&#44; regardless of the objective assessment of the dermatologist &#40;PASI&#41;&#59; in other words&#44; a patient with DLQI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>15 could not be classified as having mild disease under any circumstances&#44; regardless of the PASI score&#46; Likewise&#44; any patient with a PASI greater than 15 would be classified as having severe psoriasis&#44; regardless of the impact of the disease on quality of life&#44; and no patient with PASI less than 7 would be classified as having severe psoriasis&#44; regardless of the impact on quality of life &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">The more appropriate characterization of patients with psoriasis according to their severity can better address needs that so far have not been met&#46; First&#44; it would homogenize groups of patients included in clinical trials&#46; Second&#44; the benefit risk assessment &#40;efficacy versus toxicity and costs&#41; that form the basis for therapeutic decisions could be adapted more exactly to the real needs of the patient&#44; thereby avoiding possible overtreatment or undertreatment&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">Another methodological limitation of the present study to take into account is that fact that a limited number of dermatologists participated &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>6&#41;&#44; and so the conclusions reached cannot be considered as robust as a consensus document&#46; Nevertheless&#44; we believe that the proposed definition and classification of moderate and severe psoriasis agreed by this working group&#44; which included experts in the management of psoriasis&#44; may serve as a starting point for debate in a representative group of experts following an appropriate method &#40;for example the Delphi method or similar&#41;&#46; Such a consensus could be used and implemented in everyday clinical practice&#44; and would without doubt lead to improved treatment of patients with psoriasis in Spain&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Ethical Responsibilities</span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Protection of human and animal subjects</span><p id="par0105" class="elsevierStylePara elsevierViewall">The authors declare that no experiments were performed on humans or animals for this investigation&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Confidentiality of data</span><p id="par0110" class="elsevierStylePara elsevierViewall">The authors declare that they have followed their hospital&#39;s protocol on the publication of data concerning patients&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Right to privacy and informed consent</span><p id="par0115" class="elsevierStylePara elsevierViewall">The authors declare that patient data do not appear in this article&#46;</p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Funding</span><p id="par0120" class="elsevierStylePara elsevierViewall">For the present study&#44; Celgene collaborated in the organization of meetings and the literature search performed by the independent scientific consultancy&#46; Nobody associated with Celgene participated in drafting the proposals or had input in other content produced by this working group or in drafting the manuscript&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Conflicts of Interest</span><p id="par0125" class="elsevierStylePara elsevierViewall">Mar Llamas-Velasco has participated in clinical trials&#44; research projects&#44; and training and consulting activities with the following companies&#58; Abbvie&#44; Celgene&#44; Galderma&#44; Janssen&#44; Leo-Pharma&#44; Lilly&#44; Novartis&#44; and Pfizer&#46;</p><p id="par0130" class="elsevierStylePara elsevierViewall">Pablo de la Cueva has participated as consultant and&#47;or investigator and&#47;or speaker for Abbvie&#44; Almirall&#44; Biogen&#44; Boehringer&#44; Celgene&#44; Janssen&#44; Leo-Pharma&#44; Lilly&#44; MSD&#44; Novartis&#44; Pfizer&#44; and UCB&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">Jaume Notario Rosa has received honoraria for consulting and training activities from Abbvie&#44; Celgene&#44; Janssen&#44; Leo-Pharma&#44; Lilly&#44; MSD&#44; Novartis&#44; and Pfizer&#46; He has participated in clinical trials and research projects sponsored by Abbvie&#44; Janssen&#44; MSD&#44; Novartis&#44; and Pfizer&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">Leandro Mart&#237;nez-Pilar has participated in research projects&#44; and training and consulting activites with the following companies&#58; Abbvie&#44; Celgene&#44; Janssen&#44; Leo-Pharma&#44; MSD&#44; Novartis&#44; and Pfizer&#46;</p><p id="par0145" class="elsevierStylePara elsevierViewall">Antonio Martorell has participated in training and consulting activities with the following companies&#58; Abbvie&#44; Celgene&#44; Janssen&#44; Isdin&#44; MSD&#44; Novartis&#44; and Pfizer&#46;</p><p id="par0150" class="elsevierStylePara elsevierViewall">David Moreno-Ram&#237;rez has participated in research projects&#44; and training and consulting activities with the following companies&#58; Abbvie&#44; Celgene&#44; Janssen&#44; Leo-Pharma&#44; Lilly&#44; MSD&#44; Novartis&#44; and Pfizer&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres949058"
          "titulo" => "Abstract"
          "secciones" => array:5 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Introduction"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Objective"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Material and methods"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Results"
            ]
            4 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec921165"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres949059"
          "titulo" => "Resumen"
          "secciones" => array:5 [
            0 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Introducci&#243;n"
            ]
            1 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Objetivo"
            ]
            2 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Material y m&#233;todos"
            ]
            3 => array:2 [
              "identificador" => "abst0045"
              "titulo" => "Resultados"
            ]
            4 => array:2 [
              "identificador" => "abst0050"
              "titulo" => "Conclusiones"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec921166"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Method"
        ]
        6 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Results"
        ]
        7 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Discussion"
        ]
        8 => array:3 [
          "identificador" => "sec0025"
          "titulo" => "Ethical Responsibilities"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Protection of human and animal subjects"
            ]
            1 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Confidentiality of data"
            ]
            2 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Right to privacy and informed consent"
            ]
          ]
        ]
        9 => array:2 [
          "identificador" => "sec0045"
          "titulo" => "Funding"
        ]
        10 => array:2 [
          "identificador" => "sec0050"
          "titulo" => "Conflicts of Interest"
        ]
        11 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2017-02-19"
    "fechaAceptado" => "2017-07-02"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec921165"
          "palabras" => array:5 [
            0 => "Psoriasis"
            1 => "Moderate-to-severe"
            2 => "Severity"
            3 => "Criterion"
            4 => "Moderate"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec921166"
          "palabras" => array:5 [
            0 => "Psoriasis"
            1 => "Moderada-grave"
            2 => "Gravedad"
            3 => "Criterio"
            4 => "Moderada"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Introduction</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The Psoriasis Area Severity Index &#40;PASI&#41; is the most widely used scale for assessing the severity of psoriasis and for therapeutic decision making&#46; On the basis of the PASI score&#44; patients have been stratified into 2 groups&#58; mild disease and moderate-to-severe disease&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Objective</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">To draft a proposal for the definition and characterization of moderate psoriasis based on PASI and Dermatology Life Quality Index &#40;DLQI&#41; scores&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Material and methods</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">A group of 6 dermatologists with experience in the treatment of psoriasis undertook a critical review of the literature and a discussion of cases to draft a proposal&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Results</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">In order of priority&#44; PASI&#44; DLQI&#44; and body surface area &#40;BSA&#41; are the parameters to be used in daily practice to classify psoriasis as mild&#44; moderate&#44; or severe&#46; Severity should be assessed on the basis of a combined evaluation and interpretation of the PASI and DLQI&#46; And 3&#44; PASI and DLQI should carry equal weight in the determination of disease severity&#46; On this basis&#44; psoriasis severity was defined using the following criteria&#58; mild&#44; PASI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>7 and DLQI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>7&#59; moderate&#44; PASI<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>7-15 and DLQI<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>5-15 &#40;classified as severe when difficult-to-treat sites are affected or when there is a significant psychosocial impact&#41;&#59; severe&#44; PASI &#62;<span class="elsevierStyleHsp" style=""></span>15&#44; independently of the DLQI score&#46;</p></span> <span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Conclusions</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">A more precise classification of psoriasis according to disease severity will improve the risk-benefit assessment essential to therapeutic decision making in these patients&#46;</p></span>"
        "secciones" => array:5 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Introduction"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Objective"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Material and methods"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Results"
          ]
          4 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Conclusions"
          ]
        ]
      ]
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Introducci&#243;n</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">El <span class="elsevierStyleItalic">Psoriasis Area Severity Index</span> &#40;PASI&#41; es la escala de medida m&#225;s utilizada para la valoraci&#243;n de la gravedad de la psoriasis y la toma de decisi&#243;n para la indicaci&#243;n de tratamiento&#46; Atendiendo a su valor se han diferenciado 2 grupos de pacientes&#58; psoriasis leve y moderada-grave&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Objetivo</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Elaborar una propuesta para la definici&#243;n y caracterizaci&#243;n de la psoriasis moderada mediante el PASI y el DLQI&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Material y m&#233;todos</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Un grupo de 6 dermat&#243;logos con experiencia en tratar psoriasis plante&#243; la revisi&#243;n cr&#237;tica de la literatura y discusi&#243;n de casos cl&#237;nicos para elaborar una propuesta&#46;</p></span> <span id="abst0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Resultados</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">1&#41; PASI&#44; DLQI y BSA son&#44; en orden de prioridad&#44; los par&#225;metros a emplear en la pr&#225;ctica cl&#237;nica para la clasificaci&#243;n de la psoriasis leve&#44; moderada y grave&#59; 2&#41; la evaluaci&#243;n de la gravedad debe incluir la evaluaci&#243;n e interpretaci&#243;n conjunta del PASI y del DLQI&#59; y 3&#41; la evaluaci&#243;n del PASI y del DLQI deber&#237;a tener igual relevancia a la hora de determinar la gravedad de la psoriasis&#46; Conforme a esto&#44; se definieron los siguientes criterios de caracterizaci&#243;n de psoriasis&#58; a&#41; leve&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>7 y DLQI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>7&#59; b&#41; moderada&#58; PASI 7-15 y DLQI 5-15 &#40;grave en caso de localizaciones de dif&#237;cil acceso para tratamientos o que supongan impacto psicosocial importante&#41;&#59; y c&#41; grave&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>15&#44; independientemente de la puntuaci&#243;n DLQI&#46;</p></span> <span id="abst0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Conclusiones</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Una mejor caracterizaci&#243;n de los pacientes en funci&#243;n de su gravedad permitir&#225; una mejora del balance de riesgos y beneficios en el que se fundamente la toma de decisiones terap&#233;uticas&#46;</p></span>"
        "secciones" => array:5 [
          0 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Introducci&#243;n"
          ]
          1 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Objetivo"
          ]
          2 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Material y m&#233;todos"
          ]
          3 => array:2 [
            "identificador" => "abst0045"
            "titulo" => "Resultados"
          ]
          4 => array:2 [
            "identificador" => "abst0050"
            "titulo" => "Conclusiones"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Please cite this article as&#58; Llamas-Velasco M&#44; de la Cueva P&#44; Notario J&#44; Mart&#237;nez-Pilar L&#44; Martorell A&#44; Moreno-Ram&#237;rez D&#46; Psoriasis moderada&#46; Propuesta de definici&#243;n&#46; Actas Dermosifiliogr&#46; 2017&#59;108&#58;911&#8211;917&#46;</p>"
      ]
    ]
    "multimedia" => array:4 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; BSA&#44; body surface area&#59; DLQI&#44; dermatology life quality index&#59; PASI&#44; psoriasis area suface index&#59; PGA&#44; physician global assessment&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Author&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Classification of Psoriasis Severity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Daud&#233;n et al&#46;&#44; 2016<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">7</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Indications &#40;Spanish Psoriasis Group&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate to severe&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 or BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 or DLQI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 or prior need for conventional systemic therapy&#44; biologics&#44; or phototherapy&#46; Disease considered severe&#58; if involvement of exposed areas with functional or psychosocial impact&#44; associated PsA&#44; erythrodermic psoriasis&#44; generalized or localized pustular psoriasis with functional or psychosocial impact&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Committee for Human Medicinal Products &#40;CHMP&#41; of the European Medicines Agency&#44; 2004<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">8</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Indications &#40;CHMP&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Mild to moderate&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10 or BSA<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10&#44; classified as mild or moderate depending on PGA<br>Moderate&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>10 or BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; controlled with topical agents&#44; classified as moderate depending on PGA<br>Moderate to severe&#58; BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; PASI<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleHsp" style=""></span>-<span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>20&#44; poor control with topical agents&#44; classified as moderate according to PGA &#40;also considered for involvement with highly infiltrated areas&#44; such as for example palmoplantar&#44; with BSA<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10&#41;<br>Severe&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>20 or BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>20 with justification for need for systemic treatment&#44; classified as severe according to PGA &#40;this could also be considered for involvement with highly infiltrated areas with BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Smith et al&#46;&#44; 2009<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">13</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Indications &#40;British Association Dermatology&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Severe&#58; PASI<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>10 or BSA<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>10 and DLQI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 &#40;evaluation of patients with high functional or psychosocial impact&#41;&#44; if they meet at least one of the following conditions&#58; phototherapy and systemic therapies contraindicated&#44; lack of response or intolerance of systemic therapies&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Menter et al&#46;&#44; 2011<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">15</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Indications &#40;American Association of Dermatology&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Mild&#58; BSA<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>5&#59; moderate&#58; BSA&#8805;<span class="elsevierStyleHsp" style=""></span>5-<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10&#59; severe&#58; BSA<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>10&#37;&#46; The classification of severity can vary in case of involvement of areas exposed with functional or psychosocial impact&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Mrovietz U et al&#46;&#44; 2011<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">16</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">European consensus<br>&#40;19 countries&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Mild&#58; BSA<span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>10&#44; PASI<span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>10&#44; DLQI<span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>10 &#40;can be considered moderate to severe if involvement of visible areas&#44; highly infiltrated plaques&#44; recalcitrant pruritus&#44; or substantial involvement of scalp&#44; genitals&#44; palms and soles&#44; or nails&#41;<br>Moderate to severe&#58; BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; DLQI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#46; BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; DLQI<span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>10 &#40;can be considered mild if there is no impact on QoL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1607265.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Criteria for Classification of Psoriasis &#40;Scientific Societies and European Consensus&#41;&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; BSA&#44; body surface area&#59; DLQI&#44; dermatology life quality index&#59; HRQoL&#44; health-related quality of life&#59; PASI&#44; psoriasis area severity index&#59; PGA&#44; physician global assessment&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Questions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Responses Obtained<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">1&#46; List in descending order of importance the parameters you consider should be used in dermatology practice for classifying moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">First&#58; PASI &#40;54 points&#41;&#59; second&#58; DLQI &#40;46 points&#41;&#59; third&#58; BSA &#40;44 points&#41;&#59; fourth&#58; sites inaccessible for treatments or sites with substantial psychosocial impact &#40;21 points&#41;&#59; fifth&#58; prior treatments &#40;18 points&#41;&#59; sixth&#58; PGA &#40;11 points&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">2&#46; Which of the following PASI ranges do you think would be appropriate for a patient with moderate psoriasis without having any further information available&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PASI 7-12 &#40;3&#41;&#59; PASI 5-10 &#40;2&#41;&#59; PASI 7-15 &#40;1&#41;&#59; PASI 5-15 &#40;1&#41;&#59; PASI 5-20 &#40;1&#41;&#59; PASI 10-18 &#40;1&#41;&#59; PASI 10-20 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">3&#46; Which of the following BSA ranges do you think would be appropriate for a patient with moderate psoriasis without having any further information available&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">BSA 5&#37;-10&#37; &#40;6&#41;&#59; BSA 4&#37;-9&#37; &#40;1&#41;&#59; BSA 5&#37;-15&#37; &#40;1&#41;&#59; BSA 10&#37;-20&#37; &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">4&#46; Indicate which of the following PGA categories you think would be appropriate for a patient with psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PGA 3&#44; mild to moderate &#40;6&#41;&#59; PGA 4&#44; moderate &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">5&#46; Which of the following DLQI ranges do you think would be appropriate for a patient with moderate psoriasis without having any further information available&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">DLQI&#58; 6-10&#44; moderate impact on HRQoL &#40;5&#41;&#59; DLQI&#58; 11-20&#44; high impact on HRQoL &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">6&#46; Patients with involvement of areas of difficult access for treatment &#40;nail&#44; palmoplantar&#44; genital&#44; scalp&#41; could be considered moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes &#40;4&#41;&#59; No &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">7&#46; Patients in whom psoriasis has psychosocial impact on daily living in terms of social&#44; personal&#44; or work effects should be considered moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No &#40;5&#41;&#59; Yes &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">8&#46; Which group of patients should be considered within moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No response to topical treatment &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">9&#46; Which of the following situations do you think could be considered moderate psoriasis in everyday clinical practice&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 or BSA<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44; with no negative impact on HRQoL &#40;DLQI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>5&#41; &#40;6&#41;&#59; no control with topical agents and PASI of 7-12 or BSA of 5&#37;-15&#37; &#40;5&#41;&#59; areas of difficult access for treatments or areas with a substantial psychosocial impact and PASI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>5 or BSA<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>5 &#40;3&#41;&#59; no control with topical agents and DLQI of 5&#37;-15&#37; &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1607264.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Responses only shown if used at least once&#46; For question 1&#44; a value of 9 &#40;most important&#41; to 1 &#40;least important&#41; was assigned to each response item&#44; and the values assigned to each parameter by the 6 participants were summed&#59; for the remaining questions&#44; from 2 to 9&#44; the number of experts who chose each response option is shown&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Responses to the Questions Included in the Questionnaire&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; BSA&#44; body surface area&#59; DLQI&#44; dermatology life quality index&#59; PASI&#44; psoriasis area surface index&#59; PGA&#44; physician global assessment&#59; QoL&#44; quality of life&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Case Histories&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Classification of Psoriasis Severity</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Agreed Assessment After Presentation and Discussion Within the Working Group&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Reassessment According to the Agreed Definition of the Working Group&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI&#58; 5&#46;4&#59; BSA&#58; 4&#37;&#59; PGA&#58; 3&#59; DLQI&#58; 8&#46; Severe involvement of the scalp and pubic area&#44; with small plaques on the shoulders&#46; Substantial impact on social domain&#46; Treatments&#58; topical agents&#44; systemic agents&#44; conventional agents&#44; biologics &#40;discontinued for pregnancy&#41;&#46; Classified as moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis based on DLQI score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI&#58; 2&#59; BSA&#58; 2&#37;&#59; PGA&#58; 1&#59; DLQI&#58; 12&#46; Involvement of scalp&#44; nails&#44; and face&#46; Impact on social domain&#46; Topical treatment&#46; Classified as moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis based on DLQI score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI&#58; 5&#59; BSA&#58; 5&#37;&#59; PGA&#58; 3&#59; DLQI&#58; 14&#46; Involvement of backs of hands&#44; shoulders&#44; and knees&#44; Substantial impact on work domain&#46; Treatments&#58; topical agents&#44; systemic agents&#44; conventional agents&#44; biologics&#46; Classified as mild&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis based on DLQI score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI&#58; 13&#46;8&#59; BSA&#58; 12&#37;&#59; PGA&#58; 3&#59; DLQI&#58; 4&#46; Extensive plaques on lower limbs&#44; back&#44; shoulders&#44; and backs of hands&#46; Substantial impact on work domain&#46; Intense pruritus&#46; Little impact on QoL &#40;due to advanced age&#41;&#46; Treatments&#58; topical&#44; conventional systemic agents&#46; Classified as moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis based on DLQI score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI&#58; 12&#59; BSA&#58; 13&#37;&#59; PGA&#58; 4&#59; DLQI&#58; 2&#46; Extensive involvement of forearms&#44; trunk&#44; legs&#44; back&#44; shoulders&#44; and backs of hands&#46; Substantial impact on work domain&#46; Intense pruritus&#46; Little impact on QoL&#46; Treatment&#58; topical agents Classified as moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis based on DLQI score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI&#58; 11&#59; BSA&#58; 8&#37;&#59; PGA&#58; 3&#59; DLQI&#58; 2&#46; Involvement of lower limbs&#44; little impact on QoL&#46; Treatment&#58; topical agents&#46; Classified as moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis based on DLQI score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1607266.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Classification of the Selected Case Histories&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; DLQI&#44; dermatology life quality index&#59; PASI&#44; psoriasis area severity index&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Classification of Psoriasis Severity</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PASI and DLQI Thresholds&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PASI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PASI 7-15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PASI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">DLQI<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Mild&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Severe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">DLQI 5-15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Severe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">DLQI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Moderate<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Severe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1607263.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Considered severe in case of sites of difficult access for treatments or which have substantial psychosocial impact&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Proposed Classification and Definition of Mild&#44; Moderate to Severe&#44; and Severe Psoriasis According to PASI and DLQI Thresholds&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:20 [
            0 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevalencia de la psoriasis en Espa&#241;a en la era de los agentes biol&#243;gicos"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "C&#46; Ferr&#225;ndiz"
                            1 => "J&#46;M&#46; Carrascosa"
                            2 => "M&#46; Toro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2013.12.008"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2014"
                        "volumen" => "105"
                        "paginaInicial" => "504"
                        "paginaFinal" => "509"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24569109"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46;B&#46; Kimball"
                            1 => "D&#46; Gladman"
                            2 => "J&#46;M&#46; Gelfand"
                            3 => "K&#46; Gordon"
                            4 => "E&#46;J&#46; Horn"
                            5 => "N&#46;J&#46; Korman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2008.01.006"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2008"
                        "volumen" => "58"
                        "paginaInicial" => "1031"
                        "paginaFinal" => "1042"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18313171"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Documento de consenso sobre la evaluaci&#243;n y el tratamiento de la psoriasis moderada&#47;grave del Grupo Espa&#241;ol de Psoriasis de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Puig"
                            1 => "X&#46; Bordas"
                            2 => "J&#46;M&#46; Carrascosa"
                            3 => "E&#46; Daud&#233;n"
                            4 => "C&#46; Ferr&#225;ndiz"
                            5 => "J&#46;M&#46; Hernanz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2009"
                        "volumen" => "100"
                        "paginaInicial" => "277"
                        "paginaFinal" => "286"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19463230"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis causes as much disability as other major medical diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46;R&#46; Rapp"
                            1 => "S&#46;R&#46; Feldman"
                            2 => "M&#46;L&#46; Exum"
                            3 => "A&#46;B&#46; Fleischer Jr&#46;"
                            4 => "D&#46;M&#46; Reboussin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "1999"
                        "volumen" => "41"
                        "paginaInicial" => "401"
                        "paginaFinal" => "407"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10459113"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Quality of life in patients with psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "M&#46;J&#46; Bhosle"
                            1 => "A&#46; Kulkarni"
                            2 => "S&#46;R&#46; Feldman"
                            3 => "R&#46; Balkrishnan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1477-7525-4-35"
                      "Revista" => array:5 [
                        "tituloSerie" => "Health Qual Life Outcomes"
                        "fecha" => "2006"
                        "volumen" => "4"
                        "paginaInicial" => "35"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16756666"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Impacto de la psoriasis en la calidad de vida relacionada con la salud"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "C&#46; Ferr&#225;ndiz Foraster"
                            1 => "A&#46; Garc&#237;a-D&#237;ez"
                            2 => "L&#46; Liz&#225;n Tudela"
                            3 => "L&#46; Berm&#250;dez-Rey"
                            4 => "X&#46; Badia Llach"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Med Clin &#40;Barc&#41;"
                        "fecha" => "2007"
                        "volumen" => "128"
                        "paginaInicial" => "325"
                        "paginaFinal" => "329"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Consensus document on the evaluation and treatment of moderate-to-severe psoriasis&#58; Psoriasis Group of the Spanish Academy of Dermatology and Venereology"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "E&#46; Daud&#233;n"
                            1 => "L&#46; Puig"
                            2 => "C&#46; Ferr&#225;ndiz"
                            3 => "J&#46;L&#46; S&#225;nchez-Carazo"
                            4 => "J&#46;M&#46; Hernanz-Hermosa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.13542"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2016"
                        "volumen" => "30"
                        "numero" => "Suppl 2"
                        "paginaInicial" => "1"
                        "paginaFinal" => "18"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26812550"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Committee for medical producs for human use of EMEA&#46; Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis&#46; European Medicines Agency Evaluation of Medicines for Human Use&#44; EMEA&#47;CHMP&#47;EWP&#47;2454&#47;02 &#91;consultado 10 Agos 2015&#93;&#46; Disponible en&#58; <a href="http://www.ema.europa.eu/">http&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;</a>"
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EUROPSO&#46; European patient perspectives on the impact of psoriasis&#58; The EUROPSO patient membership survey&#46; Patient Survey Group"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Dubertret"
                            1 => "U&#46; Mrowietz"
                            2 => "A&#46; Ranki"
                            3 => "P&#46;C&#46; van de Kerkhof"
                            4 => "S&#46; Chimenti"
                            5 => "T&#46; Lotti"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2006.07405.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2006"
                        "volumen" => "155"
                        "paginaInicial" => "729"
                        "paginaFinal" => "736"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16965422"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "What characterizes the severity of psoriasis&#63; Results from an epidemiological study of over 3&#44;300 patients in the Iberian region"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "A&#46; Garc&#237;a-Diez"
                            1 => "C&#46;F&#46; Foraster"
                            2 => "F&#46;V&#46; Sebasti&#225;n"
                            3 => "L&#46;L&#46; Tudela"
                            4 => "X&#46;B&#46; Llach"
                            5 => "G&#46;S&#46; Fern&#225;ndez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000111511"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatology"
                        "fecha" => "2008"
                        "volumen" => "216"
                        "paginaInicial" => "137"
                        "paginaFinal" => "151"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18216476"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Quality of psoriasis care in Germany--results of the national study PsoHealth 2007"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Augustin"
                            1 => "K&#46; Reich"
                            2 => "C&#46; Reich"
                            3 => "S&#46; Purwins"
                            4 => "S&#46; Jeff Rustenbach"
                            5 => "I&#46; Sch&#228;fer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1610-0387.2008.06807.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dtsch Dermatol Ges"
                        "fecha" => "2008"
                        "volumen" => "6"
                        "paginaInicial" => "640"
                        "paginaFinal" => "645"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18801145"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study &#40;FUTURE&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "K&#46; Reich"
                            1 => "D&#46; Thaci"
                            2 => "U&#46; Mrowietz"
                            3 => "A&#46; Kamps"
                            4 => "M&#46; Neureither"
                            5 => "T&#46; Luger"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1610-0387.2009.07120.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dtsch Dermatol Ges"
                        "fecha" => "2009"
                        "volumen" => "7"
                        "paginaInicial" => "603"
                        "paginaFinal" => "611"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19459898"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "British Association of Dermatologists&#8217; guidelines for biologic interventions for psoriasis 2009"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;H&#46; Smith"
                            1 => "A&#46;V&#46; Anstey"
                            2 => "J&#46;N&#46; Barker"
                            3 => "A&#46;D&#46; Burden"
                            4 => "R&#46;J&#46; Chalmers"
                            5 => "D&#46;A&#46; Chandler"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2009.09505.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2009"
                        "volumen" => "161"
                        "paginaInicial" => "987"
                        "paginaFinal" => "1019"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19857207"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Scoring and monitoring the severity of psoriasis&#46; What is the preferred method&#63; What is the ideal method&#63; Is PASI pass&#233;&#63; Facts and controversies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "L&#46; Naldi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.clindermatol.2009.03.001"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clinics in Dermatology"
                        "fecha" => "2010"
                        "volumen" => "28"
                        "paginaInicial" => "67"
                        "paginaFinal" => "72"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20082954"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Guidelines of care for the management of psoriasis and psoriatic arthritis&#58; Section 6&#46; Guidelines of care for the treatment of psoriasis and psoriatic arthritis&#58; case-based presentations and evidence-based conclusions"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "American Academy of Dermatology Work Group"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Menter"
                            1 => "N&#46;J&#46; Korman"
                            2 => "C&#46;A&#46; Elmets"
                            3 => "S&#46;R&#46; Feldman"
                            4 => "J&#46;M&#46; Gelfand"
                            5 => "K&#46;B&#46; Gordon"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2010.11.055"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2011"
                        "volumen" => "65"
                        "paginaInicial" => "137"
                        "paginaFinal" => "174"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21306785"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Definition of treatment goals for moderate to severe psoriasis&#58; A European consensus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "U&#46; Mrowietz"
                            1 => "K&#46; Kragballe"
                            2 => "K&#46; Reich"
                            3 => "P&#46; Spuls"
                            4 => "C&#46;E&#46; Griffiths"
                            5 => "A&#46; Nast"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00403-010-1080-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Dermatol Res"
                        "fecha" => "2011"
                        "volumen" => "303"
                        "paginaInicial" => "1"
                        "paginaFinal" => "10"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20857129"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A review of health outcomes in patients with psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "K&#46; Li"
                            1 => "A&#46;W&#46; Armstrong"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.det.2011.08.012"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatol Clin"
                        "fecha" => "2012"
                        "volumen" => "30"
                        "paginaInicial" => "61"
                        "paginaFinal" => "67"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22117868"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevalence of metabolic syndrome in patients with psoriasis&#58; A population-based study in the United Kingdom"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;M&#46; Langan"
                            1 => "N&#46;M&#46; Seminara"
                            2 => "D&#46;B&#46; Shin"
                            3 => "A&#46;B&#46; Troxel"
                            4 => "S&#46;E&#46; Kimmel"
                            5 => "N&#46;N&#46; Mehta"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/jid.2011.365"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Invest Dermatol"
                        "fecha" => "2012"
                        "volumen" => "132"
                        "paginaInicial" => "556"
                        "paginaFinal" => "562"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22113483"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Flor-Garc&#237;a A&#44; Mart&#237;nez-Valdivieso L&#44; Ortiz-Navarro MR&#46; Informe t&#233;cnico de terapias biol&#243;gicas en dermatolog&#237;a&#58; artritis psori&#225;sica y psoriasis&#46; Servicio de Salud de Castilla la Mancha&#44; mayo de 2012 &#91;consultado 10 Oct 2015&#93;&#46; Disponible en&#58; <a href="http://sescam.castillalamancha.es/">http&#58;&#47;&#47;sescam&#46;castillalamancha&#46;es&#47;</a>"
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis vulgaris&#58; An evidence-based guide for primary care"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "E&#46;A&#46; Kupetsky"
                            1 => "M&#46; Keller"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3122/jabfm.2013.06.130055"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Board Fam Med"
                        "fecha" => "2013"
                        "volumen" => "26"
                        "paginaInicial" => "787"
                        "paginaFinal" => "801"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24204077"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/15782190/0000010800000010/v1_201711300824/S1578219017303062/v1_201711300824/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6155"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Original Articles"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010800000010/v1_201711300824/S1578219017303062/v1_201711300824/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017303062?idApp=UINPBA000044"
]
Información del artículo
ISSN: 15782190
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 19 15 34
2024 Octubre 136 73 209
2024 Septiembre 142 44 186
2024 Agosto 197 65 262
2024 Julio 150 51 201
2024 Junio 159 46 205
2024 Mayo 165 50 215
2024 Abril 168 39 207
2024 Marzo 163 73 236
2024 Febrero 164 61 225
2024 Enero 149 52 201
2023 Diciembre 115 41 156
2023 Noviembre 130 94 224
2023 Octubre 97 86 183
2023 Septiembre 96 71 167
2023 Agosto 72 21 93
2023 Julio 96 69 165
2023 Junio 91 30 121
2023 Mayo 82 45 127
2023 Abril 72 34 106
2023 Marzo 82 46 128
2023 Febrero 76 42 118
2023 Enero 73 82 155
2022 Diciembre 72 47 119
2022 Noviembre 55 44 99
2022 Octubre 57 46 103
2022 Septiembre 45 56 101
2022 Agosto 40 52 92
2022 Julio 43 64 107
2022 Junio 34 47 81
2022 Mayo 157 74 231
2022 Abril 160 64 224
2022 Marzo 163 74 237
2022 Febrero 171 75 246
2022 Enero 170 88 258
2021 Diciembre 119 69 188
2021 Noviembre 140 82 222
2021 Octubre 106 101 207
2021 Septiembre 92 72 164
2021 Agosto 105 46 151
2021 Julio 132 63 195
2021 Junio 128 64 192
2021 Mayo 91 64 155
2021 Abril 195 90 285
2021 Marzo 118 53 171
2021 Febrero 146 67 213
2021 Enero 105 39 144
2020 Diciembre 73 44 117
2020 Noviembre 91 56 147
2020 Octubre 54 24 78
2020 Septiembre 76 37 113
2020 Agosto 62 44 106
2020 Julio 62 32 94
2020 Junio 54 43 97
2020 Mayo 50 35 85
2020 Abril 38 28 66
2020 Marzo 49 32 81
2020 Febrero 2 0 2
2020 Enero 4 0 4
2019 Diciembre 4 0 4
2019 Noviembre 5 0 5
2019 Septiembre 5 0 5
2019 Agosto 2 0 2
2019 Julio 8 0 8
2019 Junio 5 0 5
2019 Mayo 9 2 11
2019 Abril 17 0 17
2019 Marzo 4 0 4
2019 Febrero 1 0 1
2019 Enero 11 0 11
2018 Diciembre 4 0 4
2018 Noviembre 4 0 4
2018 Octubre 2 0 2
2018 Septiembre 3 0 3
2018 Febrero 60 34 94
2018 Enero 57 35 92
2017 Diciembre 143 45 188
2017 Noviembre 15 25 40
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Actas Dermo-Sifiliográficas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?